Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Indivumed GmbH currently faces 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This activity is handled by 1 distinct examiner and 1 distinct art unit. The company's current engagement with the patent office is concentrated on this 1 matter. With 1 pending office action, Indivumed GmbH can provide a detailed and technical response to the examiner's specific findings.
The busiest examiner, BAUSCH, SARAE L, is responsible for 1 pending office action. This count accounts for the company's total pending office action count. For practitioners, the immediate goal is to address the specific feedback from BAUSCH, SARAE L to move the biotechnology portfolio forward. The 1 distinct art unit will apply its specialized knowledge to the examination of the company's pharmaceutical claims.
Having 1 pending office action means that the company's prosecution efforts are highly focused. Practitioners should monitor the progress of this matter to ensure that the company's intellectual property goals are met. The interaction with BAUSCH, SARAE L is the key factor in the current success of the company's patent applications in the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUSCH, SARAE L | 1 | 29.8% | +44.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18137040 | COLORECTAL CANCER SUBTYPE IDENTIFIER | BAUSCH, SARAE L | 9d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18137040 | COLORECTAL CANCER SUBTYPE IDENTIFIER | BAUSCH, SARAE L | 9d |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18137040 | COLORECTAL CANCER SUBTYPE IDENTIFIER | BAUSCH, SARAE L | 1699 | §101§102§112 | Final Rejection | 9d | Pending | Apr 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial